Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

BCL-2 as therapeutic target for hematological malignancies
Guilherme Fleury Perini, Glaciano Ribeiro, Jorge Vaz Pinto Neto, et al.
Journal of Hematology & Oncology (2018) Vol. 11, Iss. 1
Open Access | Times Cited: 185

Showing 1-25 of 185 citing articles:

Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 1176
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity
Sajid Khan, Xuan Zhang, Dongwen Lv, et al.
Nature Medicine (2019) Vol. 25, Iss. 12, pp. 1938-1947
Open Access | Times Cited: 508
Advancing targeted protein degradation for cancer therapy
Brandon Dale, Meng Cheng, Kwang‐Su Park, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 10, pp. 638-654
Open Access | Times Cited: 438
Targeting BCL-2 in B-cell malignancies and overcoming therapeutic resistance
Isha Kapoor, Juraj Bodo, Brian T. Hill, et al.
Cell Death and Disease (2020) Vol. 11, Iss. 11
Open Access | Times Cited: 199
BIRC3 and BIRC5: multi‐faceted inhibitors in cancer
Raffaele Frazzi
Cell & Bioscience (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 143
The interplay between apoptosis and cellular senescence: Bcl-2 family proteins as targets for cancer therapy
Alakananda Basu
Pharmacology & Therapeutics (2021) Vol. 230, pp. 107943-107943
Closed Access | Times Cited: 127
Discovery of small molecule ligands for the von Hippel-Lindau (VHL) E3 ligase and their use as inhibitors and PROTAC degraders
Claudia J. Diehl, Alessio Ciulli
Chemical Society Reviews (2022) Vol. 51, Iss. 19, pp. 8216-8257
Open Access | Times Cited: 127
Driving E3 Ligase Substrate Specificity for Targeted Protein Degradation: Lessons from Nature and the Laboratory
Angus D. Cowan, Alessio Ciulli
Annual Review of Biochemistry (2022) Vol. 91, Iss. 1, pp. 295-319
Open Access | Times Cited: 84
Emerging biomarkers and potential therapeutics of the BCL-2 protein family: the apoptotic and anti-apoptotic context
Md. Saddam, Shamrat Kumar Paul, Mohammad Ahsan Habib, et al.
Egyptian Journal of Medical Human Genetics (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 21
Revolutionizing cancer care strategies: immunotherapy, gene therapy, and molecular targeted therapy
Aasma Zafar, Muhammad Jawad Khan, J Abu, et al.
Molecular Biology Reports (2024) Vol. 51, Iss. 1
Open Access | Times Cited: 20
Dual role of Endoplasmic Reticulum Stress-Mediated Unfolded Protein Response Signaling Pathway in Carcinogenesis
Natalia Siwecka, Wioletta Rozpędek‐Kamińska, Dariusz Pytel, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 18, pp. 4354-4354
Open Access | Times Cited: 132
Venetoclax: evidence to date and clinical potential
Luis Miguel Juárez‐Salcedo, Viraj Desai, Samir Dalia
Drugs in Context (2019) Vol. 8, pp. 1-13
Open Access | Times Cited: 106
Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatment
Xiaopeng Peng, Zhiqiang Sun, Peihua Kuang, et al.
European Journal of Medicinal Chemistry (2020) Vol. 208, pp. 112831-112831
Closed Access | Times Cited: 92
Isocitrate dehydrogenase inhibitors in acute myeloid leukemia
Xiaoyan Liu, Yuping Gong
Biomarker Research (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 89
CAR-T “the living drugs”, immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy
Delong Liu
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 88
Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Bo Yu, Delong Liu
Journal of Hematology & Oncology (2019) Vol. 12, Iss. 1
Open Access | Times Cited: 87
Discovery of PROTAC BCL-XL degraders as potent anticancer agents with low on-target platelet toxicity
Xuan Zhang, Dinesh Thummuri, Xingui Liu, et al.
European Journal of Medicinal Chemistry (2020) Vol. 192, pp. 112186-112186
Open Access | Times Cited: 83
Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors
Amr K. A. Bass, Mona S. El‐Zoghbi, El-Shimaa M. Nageeb, et al.
European Journal of Medicinal Chemistry (2020) Vol. 209, pp. 112904-112904
Closed Access | Times Cited: 80
Role of Inflammatory Mediators, Macrophages, and Neutrophils in Glioma Maintenance and Progression: Mechanistic Understanding and Potential Therapeutic Applications
Abdul Samad Basheer, Faridah Abas, Iekhsan Othman, et al.
Cancers (2021) Vol. 13, Iss. 16, pp. 4226-4226
Open Access | Times Cited: 74
Recent progress in mitochondria-targeting-based nanotechnology for cancer treatment
Jingbo Qin, Ningqiang Gong, Zhihuan Liao, et al.
Nanoscale (2021) Vol. 13, Iss. 15, pp. 7108-7118
Closed Access | Times Cited: 71
B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
Manzar Alam, Sabeeha Ali, Taj Mohammad, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10442-10442
Open Access | Times Cited: 68
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes
Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, et al.
American Journal of Hematology (2022) Vol. 98, Iss. 2, pp. 272-281
Open Access | Times Cited: 50
Harnessing the Therapeutic Potential of Biomacromolecules through Intracellular Delivery of Nucleic Acids, Peptides, and Proteins
Yu Tian, Matthew Tirrell, James L. LaBelle
Advanced Healthcare Materials (2022) Vol. 11, Iss. 12
Open Access | Times Cited: 39
Leptomeningeal Metastasis: A Review of the Pathophysiology, Diagnostic Methodology, and Therapeutic Landscape
Andrew Nguyen, Alexander T. Nguyen, Oluwaferanmi Dada, et al.
Current Oncology (2023) Vol. 30, Iss. 6, pp. 5906-5931
Open Access | Times Cited: 38
Targeting ferroptosis for leukemia therapy: exploring novel strategies from its mechanisms and role in leukemia based on nanotechnology
Muhammad Hossein Ashoub, Razieh Razavi, Kamran Heydaryan, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top